Axsome Therapeutics, Inc. (AXSM)
Health Care · Biotechnology · NASDAQ
A biopharmaceutical company developing and commercializing innovative therapies for central nervous system disorders.
What Axsome Therapeutics, Inc. does
Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) conditions. The company maintains a portfolio of proprietary products and late-stage clinical candidates targeting diseases such as depression, migraine, and sleep disorders. Axsome markets its own pharmaceutical products and continues to invest in research and development to expand its pipeline.
Themes: CNS / psychiatry, neurology, depression therapy, migraine treatment
Fundamentals
- Price$207.15 as of 2026-08-26 close
- Market cap$10.9B as of 2026-08-26
- 1-year return+71.0% 2025-08-26 close $121.15 → 2026-08-26 close $207.15
- P/En/a negative earnings
- Net margin-24.7% as of 2026-08-26
- Gross margin+93.2% as of 2026-08-26
- ROE-255.6% as of 2026-08-26
- Debt / equity2.43 as of 2026-08-26
- Revenue growth (YoY)+56.9% as of 2026-08-26
- Revenue CAGR (3y)+133.7% SEC XBRL
- Beta0.65 as of 2026-08-26
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How AXSM compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-26
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-26
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-26
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-26
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
AXSM is not currently in any published Top 10 list. Its scores are below.
Long-term score
35.9 #1456 of 1,608 scored · #178 of 198 in Health Care
Growth 98th (3-year revenue CAGR 133.7%, revenue growth year over year 56.9%) and long-term trend 58th (a "golden cross" — its 50-day average is above its 200-day); weakest is valuation (1st, price to book 129.2).
Short-term score
50.2 #659 of 1,696 scored · #127 of 239 in Health Care
Volume and participation 84th: trading volume is about normal versus its 30-day average; setup 61st: no Elliott-wave labelling currently fits its swings; weakest is trend 32nd: it is trading 10.8% below its 50-day average, the short-term trend line.
Scores as of 25 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
How Axsome Therapeutics, Inc. looks technically
Axsome Therapeutics, Inc. (AXSM) is trading 8.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 539 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 4 trading days ago (its momentum flipped negative). It made a new 20-day low about 3 trading days ago. It is 20.4% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 8.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +8.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $229.52 | $229.52 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $191.38 | $191.38 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 223.4. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 539 trading days ago — a "golden cross", a bullish long-term signal | 539 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend) | 20.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30) | 38.1 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($200.19 to $223.40) — its "stochastic" reading is 30 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 30.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 4 trading days ago (its momentum flipped negative) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $260.19 | $260.19 |
|---|---|---|
| From the 52-week high | it is 20.4% below its 52-week high (its highest price of the past year) | -20.4% |
| Above the 52-week low | it is 83.5% above its 52-week low (its lowest price of the past year) | +83.5% |
| Below the 52-week high | it is 20.4% below its highest point of the past year | 20.4% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $260.19 (set on 2026-06-18) | $260.19 |
| Given back of the 52-week move | over the past year its closes ranged ($114.10 to $255.17), and it has given back roughly a third of its rise from last year’s low — 34% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $163.47 to $167.99. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 34.0% |
| From the all-time high | it is 20.4% below its all-time high | -20.4% |
| Nearest price level | it is trading 6.9% below a resistance level at $221.41 — a price it turned at four times since 2026-06-02, most recently on 2026-08-19. Since 2024-08-26 it has 11 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +6.9% |
| All-time low | its lowest closing price on record is $1.94 (set on 2018-12-27) | $1.94 |
| Above the all-time low | it is 10577.8% above its all-time low | +10,578% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 71% of it) | 29th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $7.91 between its high and its low — about 3.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $7.91 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $200.94 and $226.48 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $200.94 – $213.71 – $226.48 |
| Typical daily range (% of price) | its price moves about 3.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.8% |
| Stretch from the 200-day average | it is trading 2.0 daily ranges above its 200-day average price (8.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.55× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-26 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.5% |
|---|---|---|
| Gap filled | a 6.0% gap up opened on 2026-06-11 has been "filled" 33 sessions ago — price traded back through the level the gap left behind, and it took 19 sessions to close | 33 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +0.85% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 17.7 percentage points (the stock lost 14.0% while the market gained 3.7%) | -17.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 13.6 percentage points (the stock lost 11.5% while the market gained 2.1%) | -13.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 15.8 percentage points (the stock gained 26.9% while the market gained 11.1%) | +15.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 52.2 percentage points (the stock gained 71.0% while the market gained 18.7%) | +52.2% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 12% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-21 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 1.8% of the share price, which is taken to mean a barrier that gives way easily. | -11.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is sitting right on the average price paid so far this year, so the typical buyer over that stretch is roughly break-even. That average is $206.50 — a volume-weighted average of daily closes over 161 sessions, not a true tick-by-tick VWAP. | +0.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is under water. That average is $213.59 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | -3.0% |
Price levels it has turned at before
AXSM last closed at $207.15 on 2026-08-26. Since 2024-08-26 it has turned at 11 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $221.41 | Resistance | 6.9% above the last close | turned there four times · 2026-06-02 to 2026-08-19 |
| $191.13 | Support | 7.7% below the last close | turned there twice · 2026-01-22 to 2026-02-03 |
| $179.00 | Support | 13.6% below the last close | turned there twice · 2026-02-06 to 2026-04-29 |
| $236.30 | Resistance | 14.1% above the last close | turned there four times · 2026-05-04 to 2026-06-24 |
| $152.86 | Support | 26.2% below the last close | turned there three times · 2025-11-25 to 2026-03-24 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $223.40.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $161.02 and $184.84 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $223.40.
This reading has stood for 8 trading days, since 2026-08-17.
Read from daily closes as of 2026-08-26.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · MACD just crossed bearish (12/26/9) · beating the market · Trading at this year’s average price paid (anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-26. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.24 mean, 1=Strong Buy…5=Strong Sell) — 21 analysts
- Mean price target$285.42 range $246.00 – $380.00; median $280.00
Analyst estimates, as of 2026-08-25. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AXSM
- Consensus EPS estimate-$0.7804 next reporting period, as of 2026-08-25
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company has a history of losses and may not achieve or sustain profitability.","Reliance on third-party manufacturers and suppliers for its commercial products.","Significant capital requirements for R&D, clinical trials, and commercial infrastructure."]
What changed in the latest 10-Q
AI-assisted comparison of AXSM's 10-Q filed 2026-05-04 against the prior one filed 2025-11-03.
Management's Discussion & Analysis (MD&A)
- Added:
- In April 2026, AUVELITY was approved for the treatment of agitation associated with dementia due to Alzheimer's disease (newer filing, 2026-05-04)
- AXS-17 is a novel, oral, investigational GABAA α2,3 receptor positive allosteric modulator that we acquired in November 2025. We plan to evaluate AXS-17 as a potential treatment for epilepsy (newer filing, 2026-05-04)
- AXS-20 is a novel, oral, investigational phosphodiesterase 10A (PDE10A) inhibitor that we acquired from Takeda in April 2026. We plan to initially evaluate AXS-20 as a potential treatment for schizophrenia and Tourette syndrome. AXS-20 has completed a proof-of-concept Phase 2 trial in 164 patients with schizophrenia and has demonstrated a favorable safety and tolerability profile in clinical studies in over 360 individuals to date (newer filing, 2026-05-04)
- In December 2025, we received formal pre-NDA meeting minutes from the FDA supporting an NDA submission for AXS-12 for the treatment of cataplexy in narcolepsy (newer filing, 2026-05-04)
- We plan to conduct two pediatric Phase 3 trials of solriamfetol in ADHD, one in children and one in adolescents (newer filing, 2026-05-04)
- We are conducting the CLARITY study, a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial of solriamfetol in patients with MDD with EDS symptoms (newer filing, 2026-05-04)
- We are conducting the FORWARD Phase 3 trial to address the FDA's feedback (for AXS-14) (newer filing, 2026-05-04)
- Removed:
- We have submitted a supplemental NDA (sNDA) to the FDA for AXS-05 in AD agitation supported by four completed Phase 3, placebo-controlled efficacy trials and a long-term safety trial. AXS-05 has been granted FDA Breakthrough Therapy designation for AD agitation (older filing, 2025-11-03)
- AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational NMDA receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor being developed for the treatment of Alzheimer's disease agitation, or AD agitation, and smoking cessation (older filing, 2025-11-03)
- In June 2025, we received a Refusal to File letter from the FDA for the NDA. To address the FDA's feedback, Axsome will conduct an additional controlled trial, which will use a fixed-dose paradigm and a 12-week primary endpoint as requested by the FDA (older filing, 2025-11-03)
- Esreboxetine, the SS-enantiomer of reboxetine, is more potent and selective than racemic reboxetine (older filing, 2025-11-03)
- Following a preliminary review, the FDA determined that the NDA was not sufficiently complete to permit a substantive review, indicating that one of the two placebo-controlled trials included in the submission was not adequate and well-controlled due to its 8-week primary endpoint and flexible-dose design, while confirming that the other trial, which utilized a 12-week primary endpoint and a fixed-dose paradigm, was adequate and well-controlled. The FDA did not raise any concerns regarding the positive results of either trial, both of which met their primary endpoints (newer filing detail in AXS-14 section, 2026-05-04)
- Reworded:
- Reference year in 10-K cross-reference changed from 'December 31, 2024' (older, 2025-11-03) to 'December 31, 2025' (newer, 2026-05-04)
- 10-K filing date changed from 'February 18, 2025' (older, 2025-11-03) to 'February 23, 2026' (newer, 2026-05-04)
- 'dedicated to the development' changed to 'focused on the development' in Overview section (newer, 2026-05-04)
- 'with' changed to 'with' in 'people living with central nervous system' (grammatical addition: 'with' added) (newer, 2026-05-04)
- Commercial Products section restructured from numbered list format (older, 2025-11-03) to paragraph format with product names and descriptions integrated differently (newer, 2026-05-04)
- AUVELITY description expanded to include 'as the first and only oral, N-methyl-D-aspartate (NMDA) receptor antagonist approved for MDD in adults and the only oral antidepressant with rapid-acting efficacy reflected in the FDA label' (newer, 2026-05-04)
- Removed sigma-1 receptor agonist designation from AUVELITY description and moved emphasis to NMDA receptor antagonist properties (newer, 2026-05-04)
- AXS-05 pipeline section now focuses solely on smoking cessation, with AD agitation removed to Commercial Products section (newer, 2026-05-04)
- 'late-stage pipeline' changed to 'diversified CNS pipeline of potentially transformative medicines' (newer, 2026-05-04)
- Solriamfetol indications restructured: 'major depressive disorder (MDD) with EDS' changed to 'major depressive disorder (\"MDD\") with EDS symptoms' (newer, 2026-05-04)
- Added detail that AXS-12 pre-NDA meeting occurred in December 2025 specifically for cataplexy in narcolepsy treatment (newer, 2026-05-04)
- Notes:
- The older filing section appears truncated at the end ('Since our incorporation in January 2012, our operations to date have included organizing and staffing our company, business planning, raising capital, developing our compounds, engaging in other discovery and preclinical activities, and the commercial launches of Auvelity, Sunosi, and Symbravo'), while the newer filing section also appears truncated ('Since our incorporation in January 2012, our operations to date have included organizing and staffing our company, business planning, raising capital, develo'). Comparison of text after this point is not possible.
- The formatting and presentation of Commercial Products differs significantly between filings, making direct textual comparison challenging; however, factual content changes have been identified.
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 12 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 2 sells ($11M) — 1 selling insider
- Last 90 days0 buys · 12 sells ($45M) — 5 selling insiders
- Last 180 days0 buys · 16 sells ($49M) — 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-06. As of 2026-08-27.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AXSM's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding AXSM as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 7,108,902
- Reported value $1,201,546,616
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
AXSM had 3,407,383 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
AXSM had 6.51% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.11 days to cover at the same settlement.
- Reported short interest (shares) 3,407,383
- Short interest (% of shares outstanding) 6.51%
- Prior settlement (shares) 3,024,030
- Reported change 12.68%
- Days to cover (reported) 5.11
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- AbbVie (ABBV)
- Eli Lilly (LLY)
- Alkermes (ALKS)
- Biohaven (BHVN)
- Sage Therapeutics
- Neurocrine Biosciences (NBIX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AXSM vs…
Frequently asked questions
What does Axsome Therapeutics, Inc. (AXSM) do?
Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) conditions. The company maintains a portfolio of proprietary products and late-stage clinical candidates targeting diseases such as depression, migraine, and sleep disorders. Axsome markets its own pharmaceutical products and continues to invest in research and development to expand its pipeline.
What sector is Axsome Therapeutics, Inc. (AXSM) in?
Axsome Therapeutics, Inc. (AXSM) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are Axsome Therapeutics, Inc.'s (AXSM) competitors?
Notable peers of Axsome Therapeutics, Inc. (AXSM) include AbbVie, Eli Lilly, Alkermes, Biohaven and Sage Therapeutics. This peer set is informational only — not financial advice.
Is Axsome Therapeutics, Inc. (AXSM) overbought or oversold right now?
Axsome Therapeutics, Inc. (AXSM) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 38, in the neutral middle (as of 2026-08-26). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AXSM come from?
Fundamentals and prices come from market data, as of 2026-08-26; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-26. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-26.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.